false

Portfolio Companies

We support companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science. Since inception in 2008, we have invested in 55 companies, realized 16 successful exits, and produced top venture returns.

style

palette-deep-blue

showJumplinks

true

Active portfolio companies

Abcuro

https://www.abcuro.com

Abcuro is developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells.

Affinia Therapeutics

https://www.affiniatx.com

Affinia is developing next-generation AAV gene therapies for rare and non-rare diseases.

Claris Bio

https://clarisbio.com

Claris is a pre-clinical stage company focused on novel therapeutics for front of the eye diseases. is a pre-clinical stage company focused on novel therapeutics for front of the eye diseases.

InStride Health

https://instride.health

Co-founded by clinicians from McLean Hospital, InStride offers technology-enhanced mental health treatment for adolescents.

Medair Therapeutics

https://www.mediartx.com

Mediar is developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.

Nocion Therapeutics

https://www.nociontx.com

Nocion is developing novel small molecule charged sodium channel blockers, “nocions,” that selectively affect actively firing nociceptors to treat neuroinflammatory indications.

Photys

https://www.photys.com

Photys is developing a new class of bifunctional drugs for phosphorylation of kinases to treat cancer.

Pykus

https://www.pykustherapeutics.com

Pykus is developing a novel intraocular polymer to replace the vitreous humor following retinal surgery.

QurAlis

https://www.quralis.com

QurAlis is developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases.

Spur Therapeutics Limited (f/k/a SwanBio)

https://www.swanbiotx.com

SwanBio is advancing AAV-based gene therapies for the treatment of neurological diseases, including adrenomyeloneuropathy.

Tuesday Health

https://www.tuesdayhealth.com

Tuesday Health is a value-based, supportive care organization that is revolutionizing the approach to serious illness and end-of-life care.

Violet Therapeutics

https://www.linkedin.com/company/violet-therapeutics

Violet is leveraging first-in-class platforms to identify, map and mine the cellular connectome at scale.

Walden BioSciences

https://www.waldenbiosciences.com

Walden BioSciences is transforming the treatment of kidney disease by restoring or preserving podocyte function.

Exited portfolio companies

Since inception, Mass General Brigham Ventures has realized 20 exits, including eight initial public offerings and 12 mergers and acquisitions. These portfolio companies are spearheading novel approaches to diagnose, prevent and treat a wide range of medical conditions.

Adheron Therapeutics

Acquired by Roche (ADR: RHHBY) Oct. 2015

Monoclonal antibody (mAb) therapy for inflammatory diseases including rheumatoid arthritis.

Amolyt Pharma

Acquired by AstraZeneca (NASDAQ: AZN) Mar. 2024

Therapeutic peptides for rare endocrine and metabolic diseases.

Annovation BioPharma

https://akouos.com

Acquired by The Medicines Company (NASDAQ: MDCO) Jan. 2015

Novel precision anesthetics.

CoStim Pharmaceuticals

Acquired by Novartis (NYSE: NVS) Feb. 2014

Next-generation immuno-oncology drugs based on T-cell costimulatory targets.

LifeImage

Acquired by Intelerad Medical Systems Sep. 2022

Digital diagnostic image sharing platform.

Lysosomal Therapeutics

Acquired by Bial Biotech Oct. 2020

Novel personalized medicine platform to treat neurodegenerative diseases, targeting the mutant GBA1 gene.

QPID Health

Acquired by eviCore Healthcare Feb. 2016

EHR analytics software – extracting insight from information.

Scorpion

Acquired by Eli Lilly (NTSE: LLY) Jan. 2025

Next-generation precision oncology company.

SeQure

Acquired by MaxCyte (NASDAQ: MXCT) Jan. 2025

Best-in-class technology to identify and manage the risks of off-target gene-editing agents.

Syntimmune

Acquired by Alexion (NASDAQ: ALXN) Nov. 2018

Advances the fight against autoimmune disease.

Tilos Therapeutics

Acquired by Merck (NYSE: MRK) June 2019

Anti-LAP antibodies: transforming the tumor microenvironment to treat cancer.

Verve Therapeutics

Acquired by Eli Lilly (NTSE: LLY) August 2025

Pioneering single-course gene editing medicines to treat cardiovascular disease.

IPOs

Akouos

IPO June 2020 (NASDAQ: AKUS); acquired by Lilly (NYSE: LLY) Dec. 2022
Precision genetic medicine company focused on inner ear disorders, including sensorineural hearing loss.